A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.

Trial Details

NCT ID
NCT05613023
Phase
PHASE3
Sponsor
Institute of Cancer Research, United Kingdom
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • SBRT
Locations (sample)
  • Cork, Ireland|51.89797,-8.47061
  • Dublin, Ireland|53.33306,-6.24889
  • Limerick, Ireland|52.66472,-8.62306
  • Auckland, New Zealand|-36.84853,174.76349
  • Middlesbrough, South Tees, United Kingdom|54.57623,-1.23483

Key Eligibility Criteria

  • Aged ≥ 18 years at randomisation
  • Histopathological confirmation of prostate adenocarcinoma with Gleason/ISUP grade group scoring within twelve months of randomisation (unless other…
  • Patients planned for 12-36 months androgen deprivation therapy
  • High risk localised prostate cancer as defined by

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →